Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasinumab in Thermal Injury Pain
NCT01053702Phase 2Withdrawn
- Sponsor
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fasinumab in procedural pain (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Change in procedural pain intensity. Status: withdrawn.
02
Drugs
fasinumab
03
Conditions
procedural pain
Beyond the preview
Go deeper on NCT01053702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01053702.